Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down. CEO Tony Johnson and Chief Financial and Operating Officer Kyle Kuvalanka told Fierce Biotech that the company is closing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Goldfinch Bio’s kidney disease treatment quelled rising protein levels in patients’ urine, but only in one of the two diseases being tested, according to initial data from a phase 2 trial.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Please provide your email address to receive an email when new articles are posted on . Biopharmaceutical company Karuna Therapeutics has announced an exclusive license agreement with biotech firm ...

Goldfinch Bio, located in Kendall Square, will focus on developing kidney disease drugs that use precision medicine — personalizing treatments to fit patients based on their genetics. Fresh off ...

Gilead Sciences will partner with Goldfinch Bio to discover, develop, and commercialize new therapeutics for diabetic kidney disease (DKD) and orphan kidney diseases, the companies said today ...

GOLDFINCH BIO - FINANCING INCLUDED INVESTORS WELLINGTON MANAGEMENT, FUNDS & ACCOUNTS MANAGED BY BLACKROCK, & GILEAD SCIENCES, YONJIN CAPITAL & OTHERS Source text for Eikon: Further company ...

Optibrium and Goldfinch Bio have announced that the company has signed a multi-year agreement to license Optibrium’s StarDrop software. The agreement will see the deployment of six of StarDrop’s ...

Focal Segmental Glomerulosclerosis Companies are Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca ...